Literature DB >> 18466428

Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease.

Jan C Rohr1, Hans J Wagner, Melchior Lauten, Hans H Wacker, Eva Jüttner, Christof Hanke, Martin Pohl, Charlotte M Niemeyer.   

Abstract

The development of lymphomas after SOT is a well-known complication of the immunosuppressive therapy necessary to prevent graft rejection. Epstein-Barr virus plays a central role in the pathogenesis of lymphomas because of its ability to transform infected cells. Differentiating PTLD from malignant lymphomas, especially HL can be challenging. We report on two patients, who developed EBV-associated lymphomas several years after SOT. A histological examination of lymph nodes led to a diagnosis of HL in both patients, who were started on chemotherapy according to current treatment protocols. A rapid and complete remission in one patient prompted us to analyze the expression pattern of EBV-latency genes. In this patient, the EBV expression profile revealed a latency type III suggesting the diagnosis of Hodgkin-like PTLD. The other patient required six courses of chemotherapy plus radiotherapy to reach a complete remission. In his tumor cells, a restricted EBV-latency type II pattern was found, suggesting a diagnosis of classical HL. These two cases demonstrate that in post-transplant lymphomas with histological features of HL, an analysis of the expression pattern of EBV proteins might aid in the differentiation between PTLD and HL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18466428     DOI: 10.1111/j.1399-3046.2007.00816.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  6 in total

1.  Hepatic involvement by lymphoproliferative disorders post liver transplantation: PTLD.Int. Survey.

Authors:  Morteza Izadi; Mozhgan Fazel; Seyed Hasan Saadat; Saeed Taheri
Journal:  Hepatol Int       Date:  2011-03-30       Impact factor: 6.047

2.  Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Authors:  Aaron S Rosenberg; Andreas K Klein; Robin Ruthazer; Andrew M Evens
Journal:  Am J Hematol       Date:  2016-04-26       Impact factor: 10.047

3.  Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive.

Authors:  Emily McKeown; Janet E Pope; Suzanne Leaf
Journal:  Open Rheumatol J       Date:  2009-07-13

4.  Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder in a kidney transplant recipient: a diagnostic pitfall.

Authors:  Taro Mohri; Yoshihiro Ikura; Asako Hirakoso; Masashi Okamoto; Masakatsu Hishizawa; Akifumi Takaori-Kondo; Seiichi Kato; Shigeo Nakamura; Kai Yoshimura; Hidetoshi Okabe; Yasuhiro Iwai
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

Review 5.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

6.  The frequency of Epstein-Barr virus among hemodialysis patients, Ahvaz, Iran.

Authors:  Rahil Nahid Samiei; Shahab Mahmoudvand; Somayeh Shokri; Manoochehr Makvandi; Heshmatollah Shahbazian; Roya Pirmoradi; Shokouh Shayanpur; Kimia Makvandi; Sepideh Nowrozi
Journal:  Iran J Microbiol       Date:  2019-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.